 WAKEFIELD, Mass., April 28, 2021 GLOBE NEWSWIRE -- Innovation Pharmaceuticals OTCQB:IPIX the Company, a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50 percent of the total targeted number of randomized trial participants n120 in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients see NCT04784897. 